Frontiers in Neurology (Jun 2024)

Exploring MAP2K3 as a prognostic biomarker and potential immunotherapy target in glioma treatment

  • Bei Pu,
  • Bei Pu,
  • Shi Feng,
  • Lijuan Gu,
  • Daniel Smerin,
  • Zhihong Jian,
  • Xiaoxing Xiong,
  • Liang Wei

DOI
https://doi.org/10.3389/fneur.2024.1387743
Journal volume & issue
Vol. 15

Abstract

Read online

Glioma, the most prevalent primary brain tumor in adults, is characterized by significant invasiveness and resistance. Current glioma treatments include surgery, radiation, chemotherapy, and targeted therapy, but these methods often fail to eliminate the tumor completely, leading to recurrence and poor prognosis. Immune checkpoint inhibitors, a class of commonly used immunotherapeutic drugs, have demonstrated excellent efficacy in treating various solid malignancies. Recent research has indicated that unconventional levels of expression of the MAP2K3 gene closely correlates with glioma malignancy, hinting it could be a potential immunotherapy target. Our study unveiled substantial involvement of MAP2K3 in gliomas, indicating the potential of the enzyme to serve as a prognostic biomarker related to immunity. Through the regulation of the infiltration of immune cells, MAP2K3 can affect the prognosis of patients with glioma. These discoveries establish a theoretical foundation for exploring the biological mechanisms underlying MAP2K3 and its potential applications in glioma treatment.

Keywords